even though this has been prompted by the need to respond better to threats like pandemic influenza,have been clear that everything that i'm talking about and that you'll hear from my colleagues relates not only from pandemic influenza but for something that is highly predictable, seasonal flu. so if we get the platform advances that we hope to get from the research that's going on now, we will have solved the problem that's unpredictable as well as one that's imminently predictable. thank you. >> thank you, dr. fauci. we'll hear from our next two speakers thunder we'll take q and a from those in the room and on the web. our next speaker will speak about influenza vaccines the next generation. dr. gary nabel director of research center at the institute of ailery and research diseases. dr. nabel. >> thank you. what i'd like to do is to share with you some of the perspectives that we have here at n.i.h. i direct the vaccine research center. and what we're trying to do in our efforts here is not so much prepare for defendant distribution of vaccine -- prepare for direct defendant distri

we set up and approach in 2005, 2006 for pandemic influenza. for vaccines, three areas.stockpiling and acquisitions, i will concentrate quite a bit on the vaccines, moving forward with the technologies that are right for coming of age to be used in the coming years. with the stockpiling efforts, in an effort that we put quite a bit of emphasis on, how can we build manufacturing infrastructure probe -- egg based supply with retrofitting those facilities and the new still based manufacturing facilities as we go forward with recombinant based manufacturing facilities. the influence of vaccines provided more robust, scalable vaccine platform being less tolerable, as we saw this year, being able to grow very well. we awarded six contracts since 2005. we took an approach with many candidates going forward that would make it to the market. we had some requirements not only to develop pandemic vaccines that seasonal vaccines with a commitment for domestic manufacture and surge capacity of 1 fifty million doses. that is the commitment they make and the hurdle they have to jump. t

and oceanside's, population, refugees, trafficking persons, and in her spare time, avian and pandemic influenza. but thank you again, and please help welcome my friend and colleague, maria otero. [applause] >> it is a pleasure to be with you and presence and also through the technology. i think the technology got caught off. when i first met secretary clinton, she was first lady and we traveled together to bolivia, a country where i was born and raised. and when i worked with the microfinance organization, this was in 1996, and it was even then that secretary clinton was working tirelessly on some of the issues that she mentioned today, including empowering women. i have watched her do this work for many years. i cannot tell you what a distinct and unique honor is to be part of her leadership team and to be representing latinos also in this department and throughout the work that we do. as undersecretary of state for democracy and global affairs, we organize several bureaus. we have three bureaus -- one dedicated to issues related to democracy, human rights, and labor. i second is focused on po

but what i think what we're really trying to do with influenza vaccine, there is a curve as the pandemic occurs, there's a lag that we start to produce a new vaccine. this is true with seasonal vaccine. so there's a spirit of, you know, right now almost about five months before going very, very quickly we can begin to that in the vaccines. so that's where the curve is kind of flat, and then it goes up. and then that goes up. i think what we want to do is to think. we want to shift the curve to the left, so that we get vaccine sooner and faster. and those are really transformative technologies, some of which we have heard about. we also can increase the slope of the curve so we get more vaccine, more quickly. both of those things can happen here. i want to say a word about regulatory science, because i think something you heard in some of the remarks here is that we really play an important role for the public, and more commonly conceived about being sure these products are safe. but we are also particularly with vaccines and gazed at every step of the way here and trying to get something

give the influence that its h and its n for the purposes of today dealing with the 2009 h1n1 pandemic influenza designated by a subgroup of this h and this a but there also important proteins that could be potential targets for vaccines that i will very briefly mentioned. the matrix protein, the nucleic acid, the n protein and the anne's to begala these are potentially important i'm going to spend a minute or 211 more of them of the next few moments but i want to make this the background of what you are going to be hearing a lot of over the next hour to from individuals. having said that, the h in an met become importantly designate the differences from season to season, what we call seasonal influenza which as i am sure most of you well know, results from very slight changes which were referred to as drifts. mostly in the h and occasionally in the n. these are predictable annual occurrences every year. like clockwork we have seasonal flu. there is residual enmity in the population which means the changes so small that even if people don't get vaccinated and it gives me chest pain to say that p

if it goes the way we've seen previous influenza pandemic scope it is likely though not for sure this particular virus will incorporate itself into the regular seasonal influenza so that we will start seeing it not in a pandemic form because a considerable part of the population will have already been immune but we will see it come back and a son of -- insulate itself to the regular flow that is the reason we want to make sure many more people get vaccinated so that those people will be protected if it recycles itself back next year. >> host: dr. fauci, update us please on dealing with hiv/aids, but how it's being dealt with as far as the disease spread and also of course in your neck of the woods actually being able to fight the illness and combat when people are affected. >> guest: hiv we still have a very big global pandemic. over 33 million people infected worldwide, greater than 90% of them are in the developing world and 67% of them are in southern africa. 2.7 million new infections each year and 2 million deaths, so it is a very serious problem. even here in the united states w

, that improve care, create greater longevity and unanticipated spending for such things as influenza pandemics. these are crucial issues with the potential for significant adverse consequences for the program which must be properly addressed through a transparent process that allows for notice and calming. it sounds to me like the american medical association thinks this is a lousy idea, and i agree with them. artificial budget targets that the medicare advisory brd would have to meet leave virtually no ram for medical innovation. you know, it's unbelievable what medical science in america and across the world has done to increase people's quality of life and their longevity as a result of heart disease, for example. people who would have died in the 170's are living today healthy because they're taking prescription medications that keep their cholesterol in check, and they have access to innovative surgical procedures like stents and other things that can not only improve their quality of life but their longevity as well. if we have the medicare advisory board saying huh-uh, we're not going t

influenza. we'll start seeing it not in a pandemic form because a considerable part of the population will alreadye to it but we'll see it come back and assimilate itself into the regular seasonal flu. that is the reason why we are now want to make sure many more people get vaccinated, so those many people will be protected if it recycles itself back next year. >> host: dr. fauci, update us please on the dealing with hiv/aids, both how it is being dealt with as far as the disease spread and also of course in your neck of the woods, actually being able to fight the illness and combat it when people are infected. >> guest: well hiv we still have a very serious global pandemic. there are over 33 million people who are infected worldwide. greater than 90% of them are in the developing world, and 67% of them are in southern africa. there are 2.7 million new infections each year and two million deaths. so it is still a very, very serious problem. even here in the united states we have 56, 56,000300 new infections each year -- 56,300 new infections each year. we have to get around and stop that. it has b